Details of the Drug

General Information of Drug (ID: DMCR1MV)

Drug Name

Itraconazole

Synonyms

Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one

Indication

Disease Entry	ICD 11	Status	REF
Aspergillosis	1F20	Approved	[1]
Blastomycosis	1F22	Approved	[1]
Fungal infection	1F29-1F2F	Approved	[2]
Fusariosis	N.A.	Approved	[1]
Histoplasmosis	N.A.	Approved	[1]
Invasive candidiasis	1F23	Approved	[1]
Mycoses	1F2Z	Approved	[1]
Candidemia	1F23.3Y	Investigative	[1]
Esophageal candidiasis	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antifungal Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

705.6

Logarithm of the Partition Coefficient (xlogp)

5.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 55% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 5.1 mL/min/kg [4]
Elimination: 0.03% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 21 hours [4]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.17132 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.002% [4]
Vd: The volume of distribution (Vd) of drug is 796 +/- 185 L []
Water Solubility: The ability of drug to dissolve in water is measured as 0.000001 mg/mL [3]

Chemical Identifiers

Formula: C35H38Cl2N8O4
IUPAC Name: 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
Canonical SMILES: CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
InChI: InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
InChIKey: VHVPQPYKVGDNFY-ZPGVKDDISA-N

Cross-matching ID

PubChem CID: 55283
ChEBI ID: CHEBI:6076
CAS Number: 84625-61-6
DrugBank ID: DB01167
TTD ID: D0V4IB
VARIDT ID: DR00687
INTEDE ID: DR0895
ACDINA ID: D00337

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[6]
Hedgehog signaling pathway (HS pathway)	TT4LXBC	NOUNIPROTAC	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[11]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[12]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[13]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[16]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[17]
Interleukin-5 (IL5)	OTAFPSCO	IL5_HUMAN	Gene/Protein Processing	[17]
Lanosterol 14-alpha demethylase (CYP51A1)	OTAYHG9C	CP51A_HUMAN	Drug Response	[18]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Itraconazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[20]
Clindamycin	DM15HL8	Moderate	Decreased metabolism of Itraconazole caused by Clindamycin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[21]
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Itraconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Midostaurin	DMI6E0R	Major	Decreased metabolism of Itraconazole caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[24]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Itraconazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMTI0ZO	Major	Decreased metabolism of Itraconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Itraconazole caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[27]
Ivabradine	DM0L594	Major	Decreased metabolism of Itraconazole caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Itraconazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Bedaquiline	DM3906J	Moderate	Decreased metabolism of Itraconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[29]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Itraconazole caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[25]
Budesonide	DMJIBAW	Major	Decreased metabolism of Itraconazole caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Itraconazole caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Itraconazole caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Itraconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Cariprazine	DMJYDVK	Major	Decreased metabolism of Itraconazole caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[33]
Erdafitinib	DMI782S	Major	Decreased metabolism of Itraconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme.	Bladder cancer [2C94]	[34]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Itraconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[35]
Talazoparib	DM1KS78	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[25]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Itraconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Itraconazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
HKI-272	DM6QOVN	Major	Decreased metabolism of Itraconazole caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
LY2835219	DM93VBZ	Major	Decreased metabolism of Itraconazole caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Itraconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Itraconazole caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Itraconazole caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Itraconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Itraconazole caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Trastuzumab Emtansine	DMU1LXS	Moderate	Decreased metabolism of Itraconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Macitentan	DMP79A1	Major	Decreased metabolism of Itraconazole caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[41]
PF-04449913	DMSB068	Major	Decreased metabolism of Itraconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[42]
Vilanterol	DMF5EK1	Moderate	Decreased metabolism of Itraconazole caused by Vilanterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[43]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Itraconazole caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[44]
Levomilnacipran	DMV26S8	Major	Decreased metabolism of Itraconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[45]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Itraconazole due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[28]
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Itraconazole caused by Regorafenib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[28]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Itraconazole caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[46]
Drospirenone	DM1A9W3	Major	Decreased metabolism of Itraconazole caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[28]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Itraconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[39]
Osilodrostat	DMIJC9X	Major	Decreased metabolism of Itraconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Itraconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
Rivaroxaban	DMQMBZ1	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Rivaroxaban.	Deep vein thrombosis [BD71]	[28]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Itraconazole caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
OPC-34712	DMHG57U	Major	Decreased metabolism of Itraconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Itraconazole caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Polatuzumab vedotin	DMF6Y0L	Major	Decreased metabolism of Itraconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[49]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Itraconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[50]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Itraconazole caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[51]
Ingrezza	DMVPLNC	Major	Additive CNS depression effects by the combination of Itraconazole and Ingrezza.	Dystonic disorder [8A02]	[52]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Itraconazole caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[53]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Itraconazole caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Itraconazole caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Itraconazole caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Itraconazole caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Itraconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[25]
Bay 80-6946	DMLOS5R	Major	Decreased metabolism of Itraconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[54]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Itraconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[55]
Solifenacin	DMG592Q	Major	Decreased metabolism of Itraconazole caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[28]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Itraconazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[56]
Dexlansoprazole	DM1DBV5	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[57]
Ripretinib	DM958QB	Major	Decreased metabolism of Itraconazole caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[28]
Sunitinib	DMCBJSR	Moderate	Decreased metabolism of Itraconazole caused by Sunitinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[28]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Itraconazole caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[25]
Colchicine	DM2POTE	Major	Decreased metabolism of Itraconazole caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[58]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Itraconazole caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[59]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Itraconazole caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[28]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Itraconazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[59]
Daclatasvir	DMSFK9V	Major	Decreased metabolism of Itraconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Rifapentine	DMCHV4I	Major	Increased metabolism of Itraconazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[60]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[61]
MK-1439	DM215WE	Minor	Decreased metabolism of Itraconazole caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Itraconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Itraconazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Itraconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Itraconazole caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Itraconazole caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Itraconazole caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Maraviroc	DMTL94F	Major	Decreased metabolism of Itraconazole caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Itraconazole and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[69]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Itraconazole and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[70]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Itraconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[28]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[25]
Aliskiren	DM1BV7W	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[28]
Tolvaptan	DMIWFRL	Major	Decreased metabolism of Itraconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[28]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Itraconazole caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[71]
TP-434	DM5A31S	Minor	Decreased metabolism of Itraconazole caused by TP-434 mediated inhibition of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[72]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[73]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Itraconazole caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[28]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Itraconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[74]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Itraconazole caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[75]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Itraconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[76]
Naloxegol	DML0B41	Major	Decreased metabolism of Itraconazole caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[28]
Pemigatinib	DM819JF	Major	Decreased metabolism of Itraconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[25]
Crizotinib	DM4F29C	Major	Decreased metabolism of Itraconazole caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[28]
Brigatinib	DM7W94S	Major	Decreased metabolism of Itraconazole caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[77]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Itraconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[78]
PF-06463922	DMKM7EW	Major	Decreased metabolism of Itraconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[79]
Osimertinib	DMRJLAT	Major	Decreased metabolism of Itraconazole caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[80]
Pralsetinib	DMWU0I2	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Pralsetinib.	Lung cancer [2C25]	[81]
Capmatinib	DMYCXKL	Major	Decreased metabolism of Itraconazole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[82]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Itraconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Halofantrine	DMOMK1V	Major	Decreased metabolism of Itraconazole caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[83]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Itraconazole caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[28]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Itraconazole and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[84]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Itraconazole and Idelalisib.	Mature B-cell leukaemia [2A82]	[85]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Itraconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[86]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Itraconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[87]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Itraconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[28]
Ponatinib	DMYGJQO	Major	Decreased metabolism of Itraconazole caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[28]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[28]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Itraconazole caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[88]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Itraconazole caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[89]
Ubrogepant	DM749I3	Major	Decreased metabolism of Itraconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[90]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Itraconazole caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[91]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Itraconazole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[92]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Itraconazole due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[70]
Flibanserin	DM70DTN	Major	Decreased metabolism of Itraconazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[93]
Panobinostat	DM58WKG	Major	Decreased metabolism of Itraconazole caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[94]
Siponimod	DM2R86O	Major	Decreased metabolism of Itraconazole caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[28]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Itraconazole caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[25]
Romidepsin	DMT5GNL	Moderate	Decreased metabolism of Itraconazole caused by Romidepsin mediated inhibition of CYP450 enzyme.	Mycosis fungoides [2B01]	[95]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Itraconazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Nilotinib	DM7HXWT	Major	Decreased metabolism of Itraconazole caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Ruxolitinib	DM7Q98D	Major	Decreased metabolism of Itraconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[96]
Dasatinib	DMJV2EK	Major	Decreased metabolism of Itraconazole caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Vorapaxar	DMA16BR	Major	Decreased metabolism of Itraconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[28]
E-2007	DMJDYNQ	Minor	Decreased metabolism of Itraconazole caused by E-2007 mediated inhibition of CYP450 enzyme.	Neuropathy [8C0Z]	[25]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Itraconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[97]
S-297995	DM26IH8	Moderate	Decreased metabolism of Itraconazole caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[25]
Olaparib	DM8QB1D	Major	Decreased metabolism of Itraconazole caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[28]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Itraconazole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[98]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[99]
Istradefylline	DM20VSK	Major	Decreased metabolism of Itraconazole caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[100]
Pimavanserin	DMR7IVC	Major	Decreased metabolism of Itraconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[101]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Itraconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[32]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Itraconazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[102]
Lefamulin	DME6G97	Major	Decreased metabolism of Itraconazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[103]
Ergonovine	DM0VEC1	Major	Decreased metabolism of Itraconazole caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[104]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Itraconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[105]
ABIRATERONE	DM8V75C	Minor	Decreased metabolism of Itraconazole caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[106]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Itraconazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[107]
Relugolix	DMK7IWL	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[108]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[109]
Silodosin	DMJSBT6	Major	Decreased metabolism of Itraconazole caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[28]
Finasteride	DMWV3TZ	Moderate	Decreased metabolism of Itraconazole caused by Finasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[32]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Itraconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[110]
Riociguat	DMXBLMP	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[28]
Axitinib	DMGVH6N	Major	Decreased metabolism of Itraconazole caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Temsirolimus	DMS104F	Major	Increased metabolism of Itraconazole caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Ciclesonide	DM2NA4K	Moderate	Decreased metabolism of Itraconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme.	Respiratory system disease [CB40-CB7Z]	[111]
Upadacitinib	DM32B5U	Major	Decreased metabolism of Itraconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[112]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Itraconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[111]
Quetiapine	DM1N62C	Major	Decreased metabolism of Itraconazole caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[113]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Itraconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[114]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Itraconazole and Amisulpride.	Schizophrenia [6A20]	[28]
Avanafil	DM75CXN	Major	Decreased metabolism of Itraconazole caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[28]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Itraconazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[115]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Itraconazole caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Itraconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Ifosfamide	DMCT3I8	Moderate	Decreased metabolism of Itraconazole caused by Ifosfamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Docetaxel	DMDI269	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[116]
Trabectedin	DMG3Y89	Major	Decreased metabolism of Itraconazole caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Armodafinil	DMGB035	Minor	Decreased metabolism of Itraconazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
LEE011	DMMX75K	Major	Decreased metabolism of Itraconazole caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Vandetanib	DMRICNP	Minor	Decreased metabolism of Itraconazole caused by Vandetanib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[117]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Itraconazole caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[118]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Itraconazole caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[25]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Itraconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[28]
Fostamatinib	DM6AUHV	Major	Decreased metabolism of Itraconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[119]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Itraconazole due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[98]
As-1670542	DMV05SW	Moderate	Decreased metabolism of Itraconazole caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[25]
Apixaban	DM89JLN	Major	Decreased clearance of Itraconazole due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[28]
Brilinta	DMBR01X	Major	Decreased metabolism of Itraconazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[28]
Cabozantinib	DMIYDT4	Major	Decreased metabolism of Itraconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[28]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Itraconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[25]
Elagolix	DMB2C0E	Major	Decreased metabolism of Itraconazole caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[120]
Fluticasone	DMGCSVF	Major	Decreased metabolism of Itraconazole caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[121]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Itraconazole caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[122]
-----------


⏷ Show the Full List of 180 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 22	E00206	11048	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 20000	E00650	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Itraconazole 100 mg capsule	100 mg	Oral Capsule	Oral
Itraconazole 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Itraconazole FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076104.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9	Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
10	Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
11	The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
12	Inhibition of 11-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Biochem Pharmacol. 2017 Apr 15;130:93-103. doi: 10.1016/j.bcp.2017.01.010. Epub 2017 Jan 25.
13	Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
14	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
15	Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci. 2007 May;97(1):32-43.
16	Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes. Toxicology. 2017 May 15;383:40-49.
17	Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
18	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
19	Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48.
20	Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
21	Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
22	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
23	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
24	Multum Information Services, Inc. Expert Review Panel.
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
27	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
30	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
31	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
32	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
33	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
34	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
35	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
36	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
37	Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
38	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
39	Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
40	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
41	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
42	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43	Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
44	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
46	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
47	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
48	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
49	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
50	Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
51	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
52	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
53	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
54	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
55	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
56	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
57	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
58	Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
59	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
60	Abadie-Kemmerly S, Pankey GA, Dalvisio JR "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med 109 (1988): 844-5. [PMID: 3190036]
61	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
62	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
63	Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
64	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
66	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
67	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
68	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
70	Canadian Pharmacists Association.
71	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
72	Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
73	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
74	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
75	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
76	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
77	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
78	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
79	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
80	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
82	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
83	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
84	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
85	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
86	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
87	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
88	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
89	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
92	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
93	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
94	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
95	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
96	Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
97	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
98	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
99	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
100	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
101	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
102	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
103	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
104	Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
105	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
106	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
107	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
108	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
109	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
110	Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
111	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
112	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
113	DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
114	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
115	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
116	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
117	Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
118	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
119	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
120	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
121	Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
122	Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.